The Chicago Entrepreneur

: Good results from Alzheimer’s drug trial seen as ‘potentially very important’

Eli Lilly’s positive trial showed that the drug donanemab ‘significantly slowed cognitive and functional decline’ in patients.

Previous post : Anheuser-Busch InBev CEO says beer shouldn’t be focus of debate as Bud Light sales deteriorate
Next post Market Extra: ECB not ready to ‘pause’ rate hikes as inflation fight continues, Lagarde says